3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Renal Cell
5
Sarcoma
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Fallopian Tube Neoplasms
2
Vulvar Neoplasms
1
Recurrence
1
Neuroendocrine Tumors
1
Neoplasms
1
Liver Neoplasms
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Neuroendocrine
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Advanced Adult Hepatocellular Carcinoma
1
Interventions
Carboplatin
44
Paclitaxel
41
Cyclophosphamide
21
Topotecan
19
Cisplatin
18
Peripheral Blood Stem Cell Transplantation
15
Filgrastim
15
Docetaxel
15
Gemcitabine
13
Bevacizumab
13
liposomal doxorubicin
11
Hyperthermic Intraperitoneal Chemotherapy
11
sargramostim
9
Therapeutics
8
Immunohistochemistry
8
Psychiatric Rehabilitation
7
Drug Therapy
7
Amifostine
7
pembrolizumab
6
olaparib
6
Taxes
6
Surveys and Questionnaires
6
Melphalan
6
Flow Cytometry
6
Early Intervention, Educational
6
Chemotherapy, Adjuvant
6
niraparib
5
denileukin diftitox
5
Surgical Procedures, Operative
5
Immunoenzyme Techniques
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Ovarian Epithelial
×
tivozanib
×
Clear all
NCT01853644
2021-10-12
TIVO
Northwestern University
Phase 2
Completed
31 enrolled
12 charts